Connect Biopharma (NASDAQ:CNTB – Get Free Report) and MeiraGTx (NASDAQ:MGTX – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation and risk.
Profitability
This table compares Connect Biopharma and MeiraGTx’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Connect Biopharma | N/A | -88.21% | -74.26% |
| MeiraGTx | -140.31% | -1,065.47% | -53.33% |
Institutional and Insider Ownership
58.7% of Connect Biopharma shares are owned by institutional investors. Comparatively, 67.5% of MeiraGTx shares are owned by institutional investors. 22.6% of Connect Biopharma shares are owned by insiders. Comparatively, 7.5% of MeiraGTx shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Volatility and Risk
Analyst Ratings
This is a summary of recent ratings and price targets for Connect Biopharma and MeiraGTx, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Connect Biopharma | 1 | 0 | 3 | 1 | 2.80 |
| MeiraGTx | 1 | 1 | 5 | 1 | 2.75 |
Connect Biopharma presently has a consensus target price of $8.67, suggesting a potential upside of 243.92%. MeiraGTx has a consensus target price of $25.67, suggesting a potential upside of 178.08%. Given Connect Biopharma’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Connect Biopharma is more favorable than MeiraGTx.
Valuation and Earnings
This table compares Connect Biopharma and MeiraGTx”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Connect Biopharma | $60,000.00 | 2,373.84 | -$55.48 million | ($1.00) | -2.52 |
| MeiraGTx | $81.39 million | 9.24 | -$114.20 million | ($1.42) | -6.50 |
Connect Biopharma has higher earnings, but lower revenue than MeiraGTx. MeiraGTx is trading at a lower price-to-earnings ratio than Connect Biopharma, indicating that it is currently the more affordable of the two stocks.
Summary
Connect Biopharma beats MeiraGTx on 9 of the 14 factors compared between the two stocks.
About Connect Biopharma
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.
About MeiraGTx
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.
Receive News & Ratings for Connect Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Connect Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
